ARTIFICIAL INTELLIGENCE (AI) SERVING THE HEALTHCARE OF TOMORROW.
Artificial intelligence (AI) has become a key tool in research. Capable of analyzing vast amounts of data, it is opening up new avenues that three researchers supported by the Fondation de France are each exploring in their own way.
At the IGBMC in Strasbourg, Gabriel Malouf, a medical oncologist and head of the Molecular and Translational Oncology team, relies on AI to better understand kidney cancer. His goal: to decipher why some patients respond well to immunotherapy, while others develop resistance or side effects. To do this, his team processes up to two million data points per tumor.
In Paris, Professor Karine Clément, director of the Nutriomics laboratory (Inserm/Sorbonne University) and physician at Pitié-Salpêtrière Hospital, is exploring the role of the gut microbiota in preventing cardiovascular diseases. Using artificial intelligence, she analyzes the 100 trillion bacteria that inhabit our intestines to identify those likely to influence the development of such conditions.
Finally, in Lille, Professor Ali Amad, a hospital practitioner and lecturer at the Faculty of Medicine, leads the CALYPSO project, dedicated to the study of psychiatric disorders. His team uses AI to analyze facial expressions, voice, and even posture in patients with depression. The aim is to refine diagnosis, adapt treatments more quickly, and better anticipate the risk of relapse.
While the computational power of artificial intelligence is impressive, researchers emphasize that it does not replace intuition or scientific rigor. As Gabriel Malouf points out: “AI is a tool to answer questions, but it will not generate good answers if we do not start with well-constructed hypotheses and scientific questions.”
At the intersection of data science, medicine, and fundamental research, a shared conviction is emerging: it is from the collaboration between humans and machines that the discoveries of tomorrow will arise.
Photo credit: Cyril Marcilhacy